Novartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract surgery for surgeons and patients.

We recommend a 'Strong Buy' rating for Alcon with a $118 price target, citing new product launches and steady growth in ...

The use of Alcon equipment often requires using Alcon-manufactured instruments ... procedure used to remove the natural lens during cataract surgery. In the U.S., over 95% of cataract removal ...

The use of Alcon equipment often requires using Alcon-manufactured instruments ... procedure used to remove the natural lens during cataract surgery. In the U.S., over 95% of cataract removal ...

Analyst Jeff Johnson of Robert W. Baird maintained a Buy rating on Alcon (ALC – Research Report), retaining the price target of $110.00.

In June 2024, Alcon’s innovations from the highly anticipated UNITY portfolio, Vitreoretinal Cataract System and Cataract System, secured the FDA’s 510(k) clearance. In the second half of the ...

Alcon focused on bringing our technologies here, particularly in the space of cataract surgeries and phacoemulsification technologies; While the needs for eye treatments of cataract had spanned ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on ALC stock, giving a Buy rating yesterday. Anthony Petrone has ...

Alcon ALC has been gaining from a strong pipeline ... The company will offer a cataract-only system called UNITY CS, which ...